Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. He is a co-founder of the Australia and New Zealand Clinician Educator Network (ANZCEN) and is the Lead for the ANZCEN Clinician Educator Incubator programme. Probenecid competes with Meropenem for active tubular secretion and thus inhibits the renal excretion of Meropenem. Campylobacter jejuni Citrobacter freundii Prescribing Meropenem in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Probenecid competes with Meropenem for active tubular secretion, resulting in increased plasma concentrations of Meropenem. Escherichia coli Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Over time, however, problems such as resistance development and selection of resistant organisms have become apparent. It inhibits bacterial cell wall synthesis like other β-lactam antibiotics. 12 & 16, Chuangye Rd., Xinshi Dist., Tainan City 74144, Taiwan for  Those who are allergic to other β-lactam antibiotics are more likely to be allergic to meropenem as well. Continue anti-convulsant therapy in patients with known seizure disorders. Meropenem, from the carbapenem class, is effective against most gram-positive, gram-negative, anaerobic, and even extended beta-lactamase–producing bacteria and has good CSF penetration. Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae. When treating complicated skin and skin structure infections caused by P.aeruginosa, a dose of 1 gram every 8 hours is recommended. The walls are necessary to protect bacteria from their environment and to keep the contents of the bacterial cell together. Review the mechanism of action of ZERBAXA® (ceftolozane and tazobactam), which demonstrated in vitro activity in the presence of certain mechanisms of resistance. In a peri-postnatal study in rats described in the published literature 2, intravenous Meropenem was administered to dams from Gestation Day 17 until Lactation Day 21 at doses of 240, 500, and 1000 mg/kg/day. No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous Meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively.  It is given by injection into a vein. ... -Meningitis - meropenem-If Pseudomonas is known or suspected - NOT ertapenem. Peptostreptococcus species. At the end of a 30-minute intravenous infusion of a single dose of Meropenem for injection in healthy volunteers, mean peak plasma concentrations of Meropenem are approximately 23 mcg/mL (range 14 to 26) for the 500 mg dose and 49 mcg/mL (range 39-58) for the 1 gram dose. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.  It was approved for medical use in the United States in 1996. Proteus mirabilis Clostridium perfringens This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  For ß-lactams, including meropenem, prolonged intravenous administration is associated with lower mortality than bolus intravenous infusion in persons with whose infections are severe, or caused by bacteria that are less sensitive to meropenem, such as Pseudomonas aeruginosa.. Gram-positive bacteria Shake to dissolve and let stand until clear. Porphyromonas asaccharolytica Table 11: Hearing Loss at Post-Therapy in the Evaluable Population Treated with Meropenem. 12.4 Microbiology. In individuals with normal renal function, rapid renal elimination takes place. Meropenem is bactericidal except against Listeria monocytogenes, where it is bacteriostatic. Meropenem for injection vials re-constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of Meropenem for injection) may be stored for up to 3 hours at up to 25°C (77°F) or for 13 hours at up to 5°C (41°F). Klebsiella pneumoniae Bacteroides fragilis Clostridium difficile Meropenem for injection should be given as intravenous infusion over 30 minutes. During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with Meropenem (500 mg or 1 gram every 8 hours). Meropenem is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment. In general, PBP-binding profiles of doripenem are quite similar to those of meropenem. The recommended dose of Meropenem for injection is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. Dosage adjustment is necessary in patients with creatinine clearance 50 mL/min or less [see Dosage and Administration (2.2), Warnings and Precautions (5.8), Clinical Pharmacology (12.3)]. The most common adverse events occurring in greater than 5% of the patients were: headache (7.8%), nausea (7.8%), constipation (7.0%), diarrhea (7.0%), anemia (5.5%), and pain (5.1%). In general, resistance arises due to mutations in penicillin-binding proteins, production of metallo-β-lactamases, or resistance to diffusion across the bacterial outer membrane. Its empirical formula is C 17H 25N 3O 5S∙3H 2O with a molecular weight of 437.52. Approximate Average Concentration (mg/mL), Table 6: Meropenem Pharmacokinetic Parameters in Patients Less Than 3 Months of Age, GA less than 32 weeks PNA less than 2 weeks, GA less than 32 weeks PNA 2 weeks or older, GA 32 weeks or older PNA less than 2 weeks, GA 32 weeks or older PNA 2 weeks or older, Escherichia coli and Pseudomonas aeruginosa, Campylobacter jejuni Citrobacter freundii, Degree of Hearing Loss (in one or both ears), We comply with the HONcode standard for trustworthy health information -, Savior Lifetec Corporation Tainin Branch Injection Plant.